Origin Therapeutics Holdings (XCNQ:ORIG) Debt-to-Revenue : N/A (As of Jun. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Origin Therapeutics Holdings Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Origin Therapeutics Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was C$0.00 Mil. Origin Therapeutics Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was C$0.00 Mil. Origin Therapeutics Holdings's annualized Revenue for the quarter that ended in Jun. 2023 was C$0.00 Mil.

Origin Therapeutics Holdings Debt-to-Revenue Historical Data

The historical data trend for Origin Therapeutics Holdings's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Origin Therapeutics Holdings Debt-to-Revenue Chart

Origin Therapeutics Holdings Annual Data

Trend

Sep21

Sep22

Debt-to-Revenue

N/A

Origin Therapeutics Holdings Quarterly Data
	Mar21	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Debt-to-Revenue	Get a 7-Day Free Trial				N/A	N/A	N/A	N/A	N/A

Competitive Comparison of Origin Therapeutics Holdings's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Origin Therapeutics Holdings's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Origin Therapeutics Holdings's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Origin Therapeutics Holdings's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Origin Therapeutics Holdings's Debt-to-Revenue falls into.

Origin Therapeutics Holdings Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Origin Therapeutics Holdings's Debt-to-Revenue for the fiscal year that ended in Sep. 2022 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0	+	0)	/	N/A
	=	N/A

Origin Therapeutics Holdings's annualized Debt-to-Revenue for the quarter that ended in Jun. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0	+	0)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Jun. 2023) Revenue data.

Origin Therapeutics Holdings Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Origin Therapeutics Holdings's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.